等待开盘 09-17 09:30:00 美东时间
+0.418
+26.31%
今日重点评级关注:D. Boral Capital:维持Veritone"买入"评级,目标价从6美元升至26美元;Guggenheim:维持Dianthus Therapeutics"买入"评级,目标价从92美元升至100美元
09-10 18:01
Guggenheim analyst Debjit Chattopadhyay initiates coverage on PepGen (NASDAQ:PEPG) with a Buy rating and announces Price Target of $6.
09-09 20:58
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.87) by 19.26 percent. This is a 19.54 percent increase over losses of $(0.87) per share from the same
08-07 20:08
Aclass actionlawsuit was filed againstPepGen Inc. ($PEPG) by ...
07-17 23:24
Shares of Rent the Runway, Inc. (NASDAQ:RENT) rose sharply in today's pre-marke...
06-06 18:52
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1135136987677396993.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通:维持Cogent Biosciences(COGT)"超配"评级,目标价从21美元升至25美元</p> <p>• Chardan Capital:维持Taysha Gene Therapies(TSHA)"买入"
05-30 09:09
PepGen ends Duchenne drug program after weak Phase 2 results, pivots to DM1 treatment showing early signs of splicing correction and safety.
05-29 21:19
HC Wainwright & Co. analyst Andrew Fein maintains PepGen (NASDAQ:PEPG) with a Buy and lowers the price target from $14 to $8.
05-29 21:13
– PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs –– PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events
05-29 04:12
潜在涨幅754.7%!HC Wainwright & Co.:Alector获机构升目标价至10美元,维持"买入"评级
05-10 10:00